- Home
- IAUX vs ALEC Comparison
IAUX vs ALEC Comparison
Compare IAUX & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- ALEC
- Stock Information
- Founded
- IAUX 2020
- ALEC 2013
- Country
- IAUX United States
- ALEC United States
- Employees
- IAUX N/A
- ALEC N/A
- Industry
- IAUX
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IAUX
- ALEC Health Care
- Exchange
- IAUX Nasdaq
- ALEC Nasdaq
- Market Cap
- IAUX 408.0M
- ALEC 454.5M
- IPO Year
- IAUX N/A
- ALEC 2019
- Fundamental
- Price
- IAUX $0.67
- ALEC $3.76
- Analyst Decision
- IAUX
- ALEC Strong Buy
- Analyst Count
- IAUX 0
- ALEC 5
- Target Price
- IAUX N/A
- ALEC $20.67
- AVG Volume (30 Days)
- IAUX 15.9M
- ALEC 749.0K
- Earning Date
- IAUX 11-12-2024
- ALEC 11-06-2024
- Dividend Yield
- IAUX N/A
- ALEC N/A
- EPS Growth
- IAUX N/A
- ALEC N/A
- EPS
- IAUX N/A
- ALEC N/A
- Revenue
- IAUX $52,944,000.00
- ALEC $61,508,000.00
- Revenue This Year
- IAUX $2.31
- ALEC N/A
- Revenue Next Year
- IAUX $123.01
- ALEC $118.87
- P/E Ratio
- IAUX N/A
- ALEC N/A
- Revenue Growth
- IAUX 30.02
- ALEC N/A
- 52 Week Low
- IAUX $0.34
- ALEC $3.49
- 52 Week High
- IAUX $1.88
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- IAUX 40.06
- ALEC 35.09
- Support Level
- IAUX $0.34
- ALEC $3.57
- Resistance Level
- IAUX $1.09
- ALEC $6.14
- Average True Range (ATR)
- IAUX 0.08
- ALEC 0.48
- MACD
- IAUX -0.03
- ALEC -0.20
- Stochastic Oscillator
- IAUX 43.98
- ALEC 10.19
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.